Request a Quotation

Your Contact Information
Peptides Logo
Support and counselling under:
+49(0)3302 - 2022000 info@peptides.de
€0.00*
Light grey background with rounded corners

Cancer/Testis Antigens (CTAs)

Drawing of a sperm in a tube

Cancer-Testis Antigens are normally restricted to germline tissues, such as testis or placenta, which are immune-privileged and lack MHC class I expression. Their aberrant expression in various cancers makes them ideal targets for immunotherapy due to their minimal expression in normal somatic tissues.

Click on the tiles below to learn more about the specific features and available peptide tools for the Cancer/Testis Antigens NY-ESO-1 and PRAME:

Cancer-Testis Antigens are normally restricted to germline tissues, such as testis or placenta, which are immune-privileged and lack MHC class I expression. Their aberrant expression in various cancers makes them ideal targets for immunotherapy due to their minimal expression in normal somatic tissues.

Click on the tiles below to learn more about the specific features and available peptide tools for the Cancer/Testis Antigens NY-ESO-1 and PRAME:

NY-ESO-1: The Gold Standard CTA

Analyzing the T-cell response against NY-ESO-1 requires navigating regions of varying immunogenicity. This concise overview focuses on residues 80 to 180, highlighting its key immunodominant clusters. We contrast the applications of full-sequence peptide pools, targeted sub-pools, and individual reference epitopes, providing exact sequence coordinates and HLA restrictions for both the 86–102 Hotspot Cluster (including elongated MHC-I motifs) and the 157–170 Anchor Cluster to streamline your TCR-T validation and immune monitoring protocols.

PRAME: A Versatile Biomarker & Target

Overexpressed in malignancies like melanoma, NSCLC, and leukemia, PRAME is a prime target for T-cell-based immunotherapy. This overview outlines its biological roles in tumor development, its prognostic utility, and the applications of our full-sequence peptide pools and custom synthesis options. We introduce our ready-to-use PRAME peptides covering prevalent HLA-A*02:01, HLA-A*24, and HLA-A*03 restrictions to accelerate your TCR-T validation, adoptive T-cell therapy, and immune monitoring protocols.

NY-ESO-1: The Gold Standard CTA

Analyzing the T-cell response against NY-ESO-1 requires navigating regions of varying immunogenicity. This concise overview focuses on residues 80 to 180, highlighting its key immunodominant clusters. We contrast the applications of full-sequence peptide pools, targeted sub-pools, and individual reference epitopes, providing exact sequence coordinates and HLA restrictions for both the 86–102 Hotspot Cluster (including elongated MHC-I motifs) and the 157–170 Anchor Cluster to streamline your TCR-T validation and immune monitoring protocols.

PRAME: A Versatile Biomarker & Target

Overexpressed in malignancies like melanoma, NSCLC, and leukemia, PRAME is a prime target for T-cell-based immunotherapy. This overview outlines its biological roles in tumor development, its prognostic utility, and the applications of our full-sequence peptide pools and custom synthesis options. We introduce our ready-to-use PRAME peptides covering prevalent HLA-A*02:01, HLA-A*24, and HLA-A*03 restrictions to accelerate your TCR-T validation, adoptive T-cell therapy, and immune monitoring protocols.

This website uses cookies to ensure the best experience possible. More information...